Over-the-counter (OTC) pain medications should be the first
choice when trying to tolerate chronic pain. Ultra-addictive, narcotic pain
medications produced by big pharma companies are so rampant in today’s world.
Nutra Pharma Corp. (OTCQB: NPHC) is a biotech company working in collaboration
with its subsidiaries to develop an innovative pipeline of biopharmaceutical
products for the management of neurological disorders, cancer, autoimmune, and
infectious diseases. At the core of Nutra Pharma’s intellectual property
portfolio is a unique platform for extracting neurotoxins from Asian cobra
venom and transforming them into non-toxic therapeutics.
Nutra Pharma’s product pipeline includes Nyloxin, an OTC
pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats.
The company’s Nyloxin product is the first OTC pain reliever clinically proven
to treat moderate to severe chronic pain. The drug is available as an oral
spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps
and neuralgia and as a topical gel for treating joint pain and pain associated
with repetitive stress and arthritis.
One problem with making a pain medication from cobra venom
is the supply of cobra venom. Nutra Pharma has completed a series of projects
to update and expand the facilities that house the Asian cobras utilized for
the production of Nyloxin. Included with these updates was the addition of 100
snakes to the existing milking line to increase venom production in line with
upcoming international orders from India and China.
“We are at an amazing inflection point for the Company,” Rik
J. Deitsch, Chairman and CEO of Nutra Pharma, stated in a news release. “Over
the past few months, we have dramatically reduced costs, paid down debt and
recapitalized the share structure of the Company,” he continued. “Now we need
to focus on increasing sales for our OTC products, Nyloxin and Pet Pain-Away.
This also requires us to scale up our raw material supplies and production
facilities. The growth-limiting material for Nutra Pharma is cobra venom, the
active ingredient in our OTC products. We need to make sure that we have an
adequate supply of validated material to meet our future production needs. With
the recently announced expansion into India and China, we realize that we will
need to grow exponentially to meet these expected product orders in the coming
months. The expansion of the reptile facilities ensures that we can grow apace
with the increasing orders.”
For more information on the company, visit www.NutraPharma.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment